These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15795556)

  • 1. Levetiracetam in L-dopa-induced dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Di Raimondo G; Vanacore N; Morgante L
    Clin Neuropharmacol; 2005; 28(2):102-3. PubMed ID: 15795556
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 3. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
    Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
    Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
    Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA
    Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
    Bona JR
    J Clin Psychopharmacol; 2006 Apr; 26(2):215-6. PubMed ID: 16633158
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam as a treatment for tardive dyskinesia: a case report.
    McGavin CL; John V; Musser WS
    Neurology; 2003 Aug; 61(3):419. PubMed ID: 12913217
    [No Abstract]   [Full Text] [Related]  

  • 11. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.
    Hill MP; Brotchie JM; Crossman AR; Bezard E; Michel A; Grimée R; Klitgaard H
    Clin Neuropharmacol; 2004; 27(4):171-7. PubMed ID: 15319703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levetiracetam in tardive dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
    Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
    Bezard E; Hill MP; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Eur J Pharmacol; 2004 Feb; 485(1-3):159-64. PubMed ID: 14757136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
    CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of tardive dyskinesia with levetiracetam in a transplant patient.
    Zivković SA; Costa G; Bond G; Abu-Elmagd KM
    Acta Neurol Scand; 2008 May; 117(5):351-3. PubMed ID: 17995990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.
    Karamanakos PN; Pappas P; Marselos M
    Pharm World Sci; 2008 Jan; 30(1):1-2. PubMed ID: 17597418
    [No Abstract]   [Full Text] [Related]  

  • 17. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Merims D; Ziv I; Djaldetti R; Melamed E
    Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
    [No Abstract]   [Full Text] [Related]  

  • 18. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F; López-Ariztegui N
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone in levodopa induced dyskinesiae.
    Meco G; Fabrizio E; Alessandri A; Vanacore N; Bonifati V
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):135. PubMed ID: 9436745
    [No Abstract]   [Full Text] [Related]  

  • 20. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.